Home Induction is Effective and Safe for Moms and Babies
NATIONAL HARBOR, Md. — More than two-thirds of nulliparous women achieved vaginal delivery after outpatient induction of labor (IOL), the HOME INDUCTION randomized noninferiority trial found. Out of nearly 300 Irish women who were induced at 39 weeks’ gestation by vaginal prostaglandin (Propess/Cervidil) or osmotic cervical dilator (Dilapan-S), 72% achieved vaginal delivery. There were no […]
Axatilimab Shows Efficacy in Recurrent/Refractory GVHD
SAN DIEGO — Axatilimab achieved rapid and durable responses in patients with recurrent/refractory chronic graft-versus-host disease (cGVHD), according to the phase II AGAVE-201 trial. The highest overall response rate (ORR) was observed in patients treated with the lowest dose of axatilimab at 0.3 mg/kg every 2 weeks, with an ORR of 74% (95% CI 63-83) […]
RAF/MEK and FAK Inhibitor Combo Effective in Low-Grade Serous Ovarian Cancer
SEOUL, South Korea — The combination of avutometinib and defactinib achieved “exceptionally” high response rates in heavily pretreated patients with recurrent low-grade serous ovarian cancer (LGSOC), according to the ENGOT-ov60/GOG-3052/RAMP 201 trial. Moreover, responses were consistently high no matter how many previous lines of therapy patients received prior to study entry, reported Rachel N. Grisham […]
RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC
MADRID — First-line treatment with the RET inhibitor selpercatinib (Retevmo) achieved superior outcomes in both medullary thyroid cancer (MTC) and advanced non-small cell lung cancer (NSCLC), according to results from two phase III trials presented here. In the LIBRETTO-531 trial, selpercatinib resulted in superior progression-free survival (PFS) and treatment failure-free survival (TFFS) compared with the […]
Robust PSA Drops With Radionuclide Therapy in Castration-Resistant Prostate Cancer
ORLANDO — An investigational radionuclide therapy targeting prostate-specific membrane antigen (PSMA) achieved biochemical responses in 70% of patients with castration-resistant prostate cancer (CRPC), and prostate-specific antigen (PSA) reductions in all but one patient, enrolled in a small preliminary clinical trial. Overall, 22 of 23 patients had some degree of PSA decline in response to fractionated […]
Intermittent fasting may reverse type 2 diabetes, according to study: Study finds people with diabetes who fast intermittently may no longer need medication
After an intermittent fasting diet intervention, patients achieved complete diabetes remission, defined as an HbA1c (average blood sugar) level of less than 6.5% at least one year after stopping diabetes medication, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism. Intermittent fasting diets have become popular in recent […]
AML Study Suggests Intensive Chemo Unnecessary Before Allo-HCT
NEW ORLEANS — Patients with relapsed or refractory acute myeloid leukemia (AML) achieved similar outcomes with allogeneic hematopoietic stem-cell transplant (allo-HCT) whether they went to transplant as soon as possible or underwent intensive salvage chemotherapy first, the randomized ASAP trial suggested. At day 56 post-transplant, complete remission (CR) rates were a similar 84.1% for patients […]
‘Senolytic’ Therapy Shows Promise in Neovascular Eye Disease
NEW YORK CITY — An investigational drug targeting senescent cells achieved sustained improvement in visual acuity in patients with diabetic macular edema (DME) or neovascular age-related macular degeneration (AMD), a small pilot study showed. After single doses of UBX1325, four of eight evaluable patients with advanced DME had at least 10 letters of improvement in […]
P53 Antagonist Shows Early Activity in Advanced Liposarcoma
CHICAGO — Almost 90% of patients with metastatic liposarcoma achieved disease control with an investigational drug targeting p53 suppression, according to an early study reported at the American Society of Clinical Oncology (ASCO) annual meeting. The results showed that 24 of 32 patients with de-differentiated liposarcoma and MDM2 amplification had stable disease and four other […]